⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Captor Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Captor Therapeutics
↗Wroclaw, Poland
Captor Therapeutics is a Polish-Swiss biopharmaceutical company specializing in Targeted Protein Degradation (TPD) technology. The company focuses on discovering and developing breakthrough therapeutics for severe conditions, particularly in oncology and autoimmune diseases, by targeting proteins previously considered "undruggable."
Operating with laboratories in Wroclaw, Poland, and a business development hub in Basel, Switzerland, Captor utilizes its proprietary Optigrade™ platform to integrate protein engineering, structural biology, and molecular modeling. The company aims to address high unmet medical needs by developing novel degraders with optimized pharmacological properties.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology and Autoimmune Therapeutics
SIZE & FINANCIALS
Employees:51-200
Revenue:$0.5M-$2M
Founded:2015
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
STOCK
Exchange:Warsaw Stock Exchange
Ticker:CTX
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Small molecule, Targeted Protein Degradation (TPD)
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Captor GmbH (Basel, Switzerland)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Tom Shepherd - CEO
Michał Walczak - CSO / Member of Management Board
Anna Pawluk - COO
Adam Łukojć - CFO
Scientific Founders:Michał Walczak, Sylvain Cottens
LINKS
Website:captortherapeutics.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Captor Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.